Outsourcing Drug Development And Manufacturing: How CMOS/CDMOS Drive Industry Growth

By Tristan Passeggiati, executive account manager at Asahi Kasei Bioprocess

Outsourcing drug development and manufacturing isn't just a trend for startups; it's increasingly a strategic imperative for pharmaceutical companies of all sizes, including established big pharma players. While smaller biotechs leverage Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) to overcome resource limitations, larger firms utilize them to enhance flexibility, manage niche product lines, or free up internal capacity to focus on core competencies like R&D and marketing.

This reliance highlights a fundamental shift in how the industry approaches production and scalability to meet ever-growing demands. Dive deeper into why both small and large pharma benefit from outsourcing by reading the full article.